vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与Digimarc CORP（DMRC）财务数据对比。点击上方公司名可切换其他公司
CHAMPIONS ONCOLOGY, INC.的季度营收约是Digimarc CORP的1.7倍（$15.0M vs $8.9M），CHAMPIONS ONCOLOGY, INC.净利率更高（1.8% vs -47.2%，领先49.0%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs 2.9%），Digimarc CORP自由现金流更多（$895.0K vs $-2.0M），过去两年CHAMPIONS ONCOLOGY, INC.的营收复合增速更高（11.8% vs -5.3%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
CSBR vs DMRC — 直观对比
营收规模更大
CSBR
是对方的1.7倍
$8.9M
营收增速更快
CSBR
高出8.6%
2.9%
净利率更高
CSBR
高出49.0%
-47.2%
自由现金流更多
DMRC
多$2.9M
$-2.0M
两年增速更快
CSBR
近两年复合增速
-5.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $8.9M |
| 净利润 | $268.0K | $-4.2M |
| 毛利率 | 51.7% | 63.5% |
| 营业利润率 | 1.2% | -48.2% |
| 净利率 | 1.8% | -47.2% |
| 营收同比 | 11.5% | 2.9% |
| 净利润同比 | -63.2% | 51.4% |
| 每股收益（稀释后） | $0.02 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSBRDMRC
| Q4 25 | $15.0M | $8.9M | ||
| Q3 25 | $14.0M | $7.6M | ||
| Q2 25 | $12.4M | $8.0M | ||
| Q1 25 | $17.0M | $9.4M | ||
| Q4 24 | $13.5M | $8.7M | ||
| Q3 24 | $14.1M | $9.4M | ||
| Q2 24 | $14.0M | $10.4M | ||
| Q1 24 | $12.0M | $9.9M |
净利润CSBRDMRC
| Q4 25 | $268.0K | $-4.2M | ||
| Q3 25 | $-436.0K | $-8.2M | ||
| Q2 25 | $-1.8M | $-8.2M | ||
| Q1 25 | $4.5M | $-11.7M | ||
| Q4 24 | $728.0K | $-8.6M | ||
| Q3 24 | $1.3M | $-10.8M | ||
| Q2 24 | $-109.0K | $-9.3M | ||
| Q1 24 | $-2.5M | $-10.3M |
毛利率CSBRDMRC
| Q4 25 | 51.7% | 63.5% | ||
| Q3 25 | 42.9% | 58.3% | ||
| Q2 25 | 41.1% | 58.8% | ||
| Q1 25 | 61.2% | 65.0% | ||
| Q4 24 | 44.9% | 60.8% | ||
| Q3 24 | 49.7% | 62.4% | ||
| Q2 24 | 48.2% | 66.1% | ||
| Q1 24 | 34.7% | 62.5% |
营业利润率CSBRDMRC
| Q4 25 | 1.2% | -48.2% | ||
| Q3 25 | -3.8% | -109.7% | ||
| Q2 25 | -16.2% | -105.2% | ||
| Q1 25 | 26.4% | -128.9% | ||
| Q4 24 | 5.4% | -105.1% | ||
| Q3 24 | 9.5% | -120.4% | ||
| Q2 24 | -1.9% | -96.2% | ||
| Q1 24 | -21.4% | -109.2% |
净利率CSBRDMRC
| Q4 25 | 1.8% | -47.2% | ||
| Q3 25 | -3.1% | -106.9% | ||
| Q2 25 | -14.9% | -102.6% | ||
| Q1 25 | 26.4% | -125.2% | ||
| Q4 24 | 5.4% | -99.9% | ||
| Q3 24 | 9.3% | -113.9% | ||
| Q2 24 | -0.8% | -89.3% | ||
| Q1 24 | -21.1% | -104.0% |
每股收益（稀释后）CSBRDMRC
| Q4 25 | $0.02 | $-0.18 | ||
| Q3 25 | $-0.03 | $-0.38 | ||
| Q2 25 | $-0.12 | $-0.38 | ||
| Q1 25 | $0.31 | $-0.55 | ||
| Q4 24 | $0.05 | $-0.40 | ||
| Q3 24 | $0.09 | $-0.50 | ||
| Q2 24 | $-0.01 | $-0.43 | ||
| Q1 24 | $-0.19 | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $12.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $40.2M |
| 总资产 | $30.2M | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSBRDMRC
| Q4 25 | $8.5M | $12.9M | ||
| Q3 25 | $10.3M | $12.6M | ||
| Q2 25 | $9.8M | $16.1M | ||
| Q1 25 | $3.2M | $21.6M | ||
| Q4 24 | $2.8M | $28.7M | ||
| Q3 24 | $2.9M | $33.7M | ||
| Q2 24 | $2.6M | $41.5M | ||
| Q1 24 | $4.5M | $48.9M |
股东权益CSBRDMRC
| Q4 25 | $4.2M | $40.2M | ||
| Q3 25 | $3.5M | $41.4M | ||
| Q2 25 | $3.8M | $46.5M | ||
| Q1 25 | $5.5M | $50.0M | ||
| Q4 24 | $681.0K | $61.4M | ||
| Q3 24 | $-332.0K | $70.2M | ||
| Q2 24 | $-1.9M | $77.2M | ||
| Q1 24 | $-2.1M | $84.5M |
总资产CSBRDMRC
| Q4 25 | $30.2M | $53.0M | ||
| Q3 25 | $30.5M | $55.4M | ||
| Q2 25 | $32.3M | $60.7M | ||
| Q1 25 | $30.6M | $66.5M | ||
| Q4 24 | $25.2M | $75.8M | ||
| Q3 24 | $24.9M | $85.0M | ||
| Q2 24 | $26.1M | $93.4M | ||
| Q1 24 | $26.8M | $99.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $895.0K |
| 自由现金流率自由现金流/营收 | -13.1% | 10.0% |
| 资本支出强度资本支出/营收 | 1.6% | 1.1% |
| 现金转化率经营现金流/净利润 | -6.47× | — |
| 过去12个月自由现金流最近4个季度 | $5.6M | $-12.3M |
8季度趋势，按日历期对齐
经营现金流CSBRDMRC
| Q4 25 | $-1.7M | $991.0K | ||
| Q3 25 | $600.0K | $-2.6M | ||
| Q2 25 | $6.9M | $-4.7M | ||
| Q1 25 | $490.0K | $-5.5M | ||
| Q4 24 | $-283.0K | $-4.2M | ||
| Q3 24 | $311.0K | $-7.1M | ||
| Q2 24 | $-1.8M | $-6.8M | ||
| Q1 24 | $-919.0K | $-8.4M |
自由现金流CSBRDMRC
| Q4 25 | $-2.0M | $895.0K | ||
| Q3 25 | $554.0K | $-2.8M | ||
| Q2 25 | $6.6M | $-4.9M | ||
| Q1 25 | $448.0K | $-5.5M | ||
| Q4 24 | $-377.0K | $-4.2M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | $-1.8M | $-6.9M | ||
| Q1 24 | $-1.0M | $-8.5M |
自由现金流率CSBRDMRC
| Q4 25 | -13.1% | 10.0% | ||
| Q3 25 | 4.0% | -36.9% | ||
| Q2 25 | 53.5% | -61.0% | ||
| Q1 25 | 2.6% | -59.1% | ||
| Q4 24 | -2.8% | -49.1% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | -13.0% | -66.1% | ||
| Q1 24 | -8.4% | -85.8% |
资本支出强度CSBRDMRC
| Q4 25 | 1.6% | 1.1% | ||
| Q3 25 | 0.3% | 2.9% | ||
| Q2 25 | 2.0% | 2.5% | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.7% | 0.2% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.8% | 1.1% |
现金转化率CSBRDMRC
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
